Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04941274 · ClinicalTrials.gov registry record · Phase 1
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
A Phase 1 study of Kaposi Sarcoma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
- 1
- Study location
NCT04941274: Recruiting Phase 1 study of Kaposi Sarcoma, sponsored by National Cancer Institute (NCI).
NCT04941274 is a Phase 1 study of Kaposi Sarcoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 86 participants, below the 96-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04941274, a Phase 1 study of Kaposi Sarcoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Kaposi Sarcoma (KS) is common in people with human immunodeficiency virus (HIV) but can also occur in people who do not have HIV. KS tumors usually involve the skin, but may also involve lymph nodes, lungs, bone, and gastrointestinal tract. Researchers want to see if a drug that is currently used to treat a type of breast cancer can help. Objective: To find a safe dose of abemaciclib to treat KS and to see if it can shrink lesions or tumors. Eligibility: People ages 18 and older with KS. Design: Participants will be screened with some or all of the following: Medical history Physical exam Blood and urine tests Chest x-ray and/or computed tomography scans Lung or gastrointestinal tract exam with an endoscope (a flexible instrument to examine the interior of the organ) Medicine review Heart function tests KS lesion assessment Skin sample from a KS lesion Treatment will be given in 28-day cycles. Participants will take the study drug tablets by mouth everyday. They will keep a medicine diary. They will get the study drug until their cancer gets worse or they have unacceptable side effects. Participants will have a study visit at the beginning of each cycle. At these visits, they will repeat some screening tests. They may have medical photographs taken of body surfaces. They may complete questionnaires about their quality of life. They may give skin and saliva samples. For skin samples, an area of skin will be numbed. A small circle of skin over an area affected by KS will be removed. Participants will have follow-up visits for up to 2 years after treatment ends.
Primary Outcome
The fraction of patients with toxicity noted at each dose level will be reported by grade and type of toxicity identified.
Conditions Studied
Interventions
- DRUG Abemaciclib
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 1 |
What NCT04941274 shows while recruiting
NCT04941274 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 96-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Kaposi Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Abemaciclib is the first listed.
NCT04941274 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04941274 about?
NCT04941274 is a clinical study titled "Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma". Background: Kaposi Sarcoma (KS) is common in people with human immunodeficiency virus (HIV) but can also occur in people who do not have HIV. KS tumors usually involve the skin, but may also involve lymph nodes, lungs, bone, and gastrointestinal tract. Researchers want to see if a drug that is curr...
What is the current status of trial NCT04941274?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2021-09-29. Estimated completion is 2028-06-01.
What conditions does trial NCT04941274 study?
This clinical trial studies the following conditions: Kaposi Sarcoma.
What interventions are being tested in trial NCT04941274?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT04941274?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04941274 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kaposi Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04941274's enrollment target sits among peer trials
86 4th of 13 higher than 10 of 13 other Kaposi Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kaposi Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
RECRUITING · Phase 1
-
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
RECRUITING · Phase 1
-
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
ACTIVE NOT RECRUITING · Phase 1
-
Trial of Ixazomib for Kaposi Sarcoma
RECRUITING · Phase 2
-
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI